Published by ChinaMNC · Ningerhanizuyizu

Yunnan's Herb Industry Plan: What Foreign Founders Should Know

Yunnan's 15th Five-Year Plan for traditional Chinese medicinal materials targets higher quality and processing value by 2030, with practical implications for foreign founders setting up in China's herb supply chain.

Yunnan Maps Out a Leaner, Higher-Value Herb Sector Through 2030

Yunnan Provincial People's Government has issued a plan for the traditional Chinese medicinal materials industry covering the 15th Five-Year Plan period. For foreign founders considering a China company in herbal sourcing, processing or health products, the document signals where provincial support and regulatory attention are heading. The plan was published as an illustrated policy explainer on the provincial government portal.

The headline framing is deliberate: by 2030, the province expects cultivated herb acreage to fall by 1.608 million mu, while the sector's combined output value is targeted to rise by 50 billion yuan. In short, Yunnan is trading planted area for gains in quality, processing, branding and efficiency. Foreign operators should read this as a shift from volume to value rather than a contraction of the industry.

Variety Priorities: Where the Focus Will Be

Building on the 156 varieties listed in the 2024 Yunnan Geo-authentic Medicinal Materials Catalogue, the plan sets three tiers of priority:

• Geo-authentic advantage varieties, led by the "Top Ten Yunnan Medicines": Panax notoginseng, Yunnan Paris polyphylla, Erigeron breviscapus, Dendrobium officinale, Amomum villosum, Gastrodia elata, Yunnan Poria, Yunnan Angelica sinensis, Yunnan Aucklandia and Yunnan Gentiana.
• Health-oriented specialty varieties grouped as the "Top Ten Health Resources": Yunnan Polygonatum, safflower, Bletilla striata, purple-skin Dendrobium, Phyllanthus emblica, Coix seed, Terminalia chebula, Amomum tsaoko, ginger and star anise.
• Potential cultivation varieties represented by the "Six Southern Medicines": Amomum villosum, dragon's blood, Cibotium barometz, agarwood, Orthosiphon aristatus and Dai Bai Jie.

Founders planning product lines around specific botanicals should note that these lists define where provincial attention and support are concentrated.

Standardised Cultivation and Forest-Based Growing

The plan aims to establish 200 GAP (Good Agricultural Practice) bases for medicinal materials. A priority is full GAP coverage of Wenshan Panax notoginseng bases, with orderly development of GAP bases for forest-grown varieties such as Poria, Amomum villosum, Amomum tsaoko and Phellodendron. The province also intends to develop a number of national-level high-standard raw material production bases.

On where cultivation happens, the focus is on geo-authentic herbs including Panax notoginseng, Gastrodia, Poria, Amomum villosum, Polygonatum and Phellodendron. The plan promotes forest-based cultivation and rearing, with ecological and under-forest planting bases to expand to more than 6 million mu.

Processing: From Raw Material to Semi-Processed Input

Two processing layers are emphasised. First, primary processing near production areas: the plan supports setting up origin-processing lines in geo-authentic production zones and high-standard raw material bases, linking GAP-base materials with fresh cutting, and upgrading products from basic raw materials to semi-industrialised inputs.

Second, deeper processing: enterprises are encouraged to build modern deep-processing lines and develop higher-value products, forming a series of Yunnan medicine health products. The plan also promotes research and industrialisation in daily chemical and cosmetics products and functional wellness products.

For foreign founders, this suggests opportunities in mid-stream processing and product development, where local policy support is explicit, rather than only in raw cultivation.

Market Stabilisation and Risk Monitoring

The plan addresses volatility in major and scarce varieties such as Panax notoginseng, Angelica sinensis and Paris polyphylla, proposing market-based adjustment to smooth price swings. It also calls for an information monitoring and early-warning system to flag industry risks such as blind expansion of planting and prices falling so low that farmers are hurt.

Foreign operators sourcing these materials should anticipate a more monitored market environment, with greater attention to planting data and price signals.

Food-Medicine Homology and Cross-Border Registration

Yunnan plans to develop standards for food-medicine homologous raw materials, including quality standards and production and processing specifications. It aims to complete cross-border registration for five to ten new products and is considering a "Yunnan Medicine Food-Medicine Homology Culture Festival."

The cross-border registration target is notable for founders interested in product registration pathways, though the plan does not specify which markets or products are involved.

The "Yunnan Medicine Brain" AI Initiative

The province intends to implement an artificial intelligence innovation application project called "Yunnan Medicine Brain," building an intelligent application system covering the full lifecycle of medicinal materials. It aims to develop multi-level, multi-scenario intelligent solutions in key areas of the sector.

Practical Takeaways for Foreign Founders

• Align with priority varieties. The three-tier lists indicate where provincial focus lies; product and sourcing plans built around them may fit the policy direction.
• Watch GAP and origin processing. The push for 200 GAP bases and origin-processing lines affects supplier qualification and traceability expectations.
• Consider forest-based supply. Expansion of under-forest bases to over 6 million mu may create new sourcing channels for listed varieties.
• Plan for monitoring. Early-warning systems for planting and prices suggest more data-driven market oversight.
• Track standards and registration. Food-medicine homology standards and cross-border registration targets may shape future product pathways.

This summary is based on information published by the relevant Chinese government website and is general information, not legal or tax advice.